Nitric oxide mediates inhibitory effect of losartan on angiotensin-induced contractions in hamster but not rat aorta

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 2, 2000, Pages 180-183

  Inoue, Kiyo ^a   Nishimura, Hikaru ^a   Kubota, Jiro ^a   Kitaura, Yasushi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin I; Angiotensin II; Aorta; Losartan; Nitric oxide

Indexed keywords

ANGIOTENSIN DERIVATIVE; ENZYME INHIBITOR; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ANIMAL; AORTA; ARTICLE; DRUG EFFECT; HAMSTER; IN VITRO STUDY; MALE; PHYSIOLOGY; RAT; SPECIES DIFFERENCE; SPONTANEOUSLY HYPERTENSIVE RAT; SYRIAN HAMSTER; VASOCONSTRICTION; WISTAR KYOTO RAT;

ANGIOTENSINS; ANIMALS; AORTA; CRICETINAE; ENZYME INHIBITORS; LOSARTAN; MALE; MESOCRICETUS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SPECIES SPECIFICITY; VASOCONSTRICTION;

EID: 0346046901     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.023     Document Type: Article

References (13)

1. Gradman AH, Arcuri KE, Goldberg AI et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1994; 25: 1345-50.
2. Ohlstein EH, Gellai M, Brooks DP et al. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be solely due to angiotensin II receptor antagonism. J Pharmacol & Experiment Ther 1992; 262: 595-601.
3. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertensin 1992; 19: 138-15.
4. Corriu C, Bernard S, Schott C, Stoclet JC. Effects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol 1995; 26: 688-92.
5. Inoue K, Nishimura H, Kubota J, Kawamura K. Alternative angiotensin II formation in rat arteries occurs only at very high concentrations of angiotensin I. Hypertension 1999; 34: 525-30.
6. Nishimura H, Buikema H, Baltatu O, Ganten D, Urata H. Functional evidence for alternative Ang II-forming pathways in hamster cardiovascular system. Am J Physiol 1998; 275: H1307-12.
7. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci 1996; 58: 591-7.
8. Morsing P, Adler G, Brandt-Eliasson U et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33: 1406-1413.
9. Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995; 26: 236-43.
10. Campbell DJ, Kladis A, Valentijin AJ. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovas Pharmacol 1995; 26: 233-40.
11. Cockcroit JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993; 22: 579-84.
12. Dicpinigaitis PV, Sciberras DG, Goldberg MR, Gayle YE, Rosenstreich DL. Losartan-induced bronchospasm. J Allergy Clin Immunol 1996; 98: 1128-30.
13. van Rijinsoever EW, Kwee-Zuiderwijk WJM. Angioneurotic edema attributed to the use of losartan. Arcb Intern Med 1998; 158: 2063-65.